Something strange is happening in family office capital allocation, and the surface reading of it is wrong.
The consensus narrative says family offices are abandoning fund structures and deploying directly at record rates. The data says otherwise. UBS’s 2026 Global Family Office Report found that direct investment allocations have not returned to their 2021 peak — in that year, surveyed offices allocated 13% to direct investments against 8% to funds and funds-of-funds, and every year since has been either an even split or tilted toward funds. Private equity allocation overall fell from roughly 22% of portfolios to 17%.
Yet in the same reporting cycle, advisors describe family office principals asking one question more insistently than any other: what direct deals can you actually give me access to, and what’s unique out there?
That is not a contradiction. That is a market with enormous demand and a broken discovery mechanism.
The Frustration Is Real, and It’s Compounding
Family offices have specific reasons to want out of the traditional fund relationship, and they have been accumulating.
The first is the distribution drought. Bain & Company’s 2026 Global Private Equity Report documented a rebound in deal and exit values alongside cash returns to limited partners that remained stubbornly disappointing. Committed capital that does not come back is committed capital that cannot be redeployed, and offices are increasingly unwilling to underwrite another blind pool while the last three remain outstanding.
The second is fee drag against extended hold periods. Management fees on committed capital accrue whether or not the capital is working. When funds run past their original terms — a pattern common enough that ILPA issued updated continuation vehicle disclosure guidance in 2026 — the fee math looks progressively worse to the party paying it.
The third is simply capacity. Preqin put global private equity dry powder near $3.7 trillion entering 2026. A family office looking at that figure reasonably concludes that its marginal dollar into a fund is competing with a great deal of other capital for the same assets, at prices that reflect the competition.
UBS recorded the consequence directly: 60% of surveyed family offices planned changes to strategic asset allocation within twelve months, the highest level in more than a decade of running the survey.
Why Aren’t Family Office Direct Investments Growing?
Because wanting direct exposure and being able to source it are entirely different capabilities.
A fund commitment requires diligence on a manager. A direct investment requires diligence on a company, in a sector, against a technical thesis, with no GP absorbing the work. Most family offices — even large, well-staffed ones — do not carry the headcount to originate, screen, and underwrite direct opportunities at volume.
And the discovery problem runs in both directions, which is the part almost nobody addresses.
“Family office mandates are among the hardest things in private markets to find,” says Deepesh Shivnani, Managing Partner at Ascentivelab Group. “They’re unpublished by design. There’s no database, no filing requirement, no marketing. A principal will tell you precisely what they want to buy — but only if you’re already in the room. Founders and most intermediaries never get in the room, so the capital and the opportunity sit on opposite sides of a wall neither can see through.”
The result is a market where trillions in capacity, genuine appetite for direct exposure, and thousands of qualified companies all coexist without connecting.
The Family Office Direct Deal Sourcing Problem
Ascentivelab Group built its practice around exactly this gap.
The firm operates on two sides. Its buy-side origination business runs mandate searches on behalf of institutional allocators — family offices, specialized funds, private equity, private credit, and venture — sourcing proprietary opportunities matched to current, specific criteria. Its sell-side business advises founders and owners raising between $3 million and $30 million.
The two functions are not parallel businesses. They are the same business viewed from opposite ends, and the buy-side work is what makes the sell-side work possible.
“You cannot match a company to a mandate you read about,” Shivnani says. “You match it to a mandate you discussed with the principal recently, in terms specific enough to be actionable. That relationship has to be maintained continuously, because mandates move. A family office that told you it was looking at medtech last year may be entirely elsewhere now, and nobody publishes that.”
The firm has advised on more than $1 billion in aggregate transaction volume, currently maintains over $150 million in active mandates in market, and works from an active investor pipeline exceeding $1 billion assembled across decades of direct relationships. Coverage concentrates in defense and military technology, biotech, medtech, life sciences, and applications with a defensible competitive edge — capital-intensive sectors where technical diligence is hardest and generalist sourcing is least effective.
The Segment Where This Matters Most
The access problem is sharpest in the range Ascentivelab Group targets.
Companies raising $3 million to $30 million occupy a structural blind spot. Cohort data from Carta and PitchBook shows the proportion of seed-funded U.S. companies reaching a priced Series A within 24 months has fallen from roughly 30% a decade ago to 15–20% in 2026, while the PitchBook-NVCA Q1 2026 Venture Monitor put median Series A pre-money valuation at $62.0 million. Companies below that threshold with real technology and real revenue can occupy a financing blind spot.
For a family office willing to do the work, that is precisely where entry pricing can be more attractive — provided someone can find the companies and stand behind the diligence.
“The discount at this size is compensation for effort, not for quality,” Shivnani says. “The companies are good. The process to reach them is difficult, and the capital that reaches them first will price accordingly.”
Preparation as the Deliverable
For an allocator, the hidden cost of direct investing is not the capital. It is the diligence hours spent discovering that a company was never ready to transact — financials that have never been reconciled, a cap table carrying preference terms from bridge financings nobody flagged, a contract position described one way in the deck and another way in the documents.
Ascentivelab Group’s position is that this work happens before an introduction, not after it. Nothing is forwarded.
“Sending a family office something unexamined costs them real hours and costs us a relationship we spent years building,” Shivnani says. “We would rather bring one company we can fully stand behind than five we’re passing along.”
Family offices seeking mandate-matched direct opportunities, and founders raising $3 million to $30 million, can arrange an introductory conversation at ascentivelab.com.
The information provided in this article is for general informational and educational purposes only. It is not investment advice, nor an offer to sell or a solicitation of an offer to buy any security. Private market investments involve substantial risk, including total loss of capital, and are suitable only for qualified and accredited investors. Statements regarding transaction volume, mandate activity and pipeline reflect Ascentivelab Group’s own records. Past activity is not indicative of future results. Ascentivelab Group is compensated by its clients for advisory and capital introduction services and therefore has a financial interest in the subject matter of this article.
